Fri. Oct 11, 2019 12:30 PM - 2:00 PM Room 1 (Main Hall)

Chair: Stephen STAHL (University of California San Diego, California, USA)

Sponsor: H. Lundbeck A/S

Fri. Oct 11, 2019 12:30 PM - 1:30 PM Room 4 (409)

Chair: Norio FURUKORI (Department of Psychiatry, Dokkyo Medical University, Japan)

Sponsor: Otsuka Pharmaceutical Co., Ltd.
*Japanese Session

Fri. Oct 11, 2019 12:30 PM - 1:30 PM Room 6 (401+402)

Chair: Yutaka WATANABE (Department of Psychiatry, Amekudai Hospital, Japan)

Sponsors: Daiichi Sankyo Co., Ltd. / UCB Japan Co. Ltd.
*Japanese Session

Fri. Oct 11, 2019 12:30 PM - 1:30 PM Room 13 (501)

Chair: Kazuyuki NAKAGOME (National Center of Neurology and Psychiatry, Japan)

Sponsor: Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd.
*Simultaneous interpretation available for Japanese only

Fri. Oct 11, 2019 12:30 PM - 1:30 PM Room 14 (Palace Room A)

Chair: Hiroyuki UCHIDA (Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan)

Sponsor: Mitsubishi Tanabe Pharma Corporation
*Japanese Session

Fri. Oct 11, 2019 12:30 PM - 1:30 PM Room 15 (Palace Room B)

Chair: Chiaki KAWANISHI (Department of Neuropsychiatry, Sapporo Medical University Graduate School of Medicine, Japan)

Sponsor: Pfizer Japan Inc. / Sumitomo Dainippon Pharma Co., Ltd.
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 1 (Main Hall)

Chair: Teruhiko HIGUCHI (Japan Depression Center, Japan)

Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 2 (411+412)

Chair: Norio OZAKI (Department of Psychiatry, Nagoya University Graduate School of Medicine, Japan)

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 3 (413+414)

Chair: Masaru MIMURA (Department of Neuropsychiatry, Keio University School of Medicine, Japan)

Sponsor: Eli Lilly Japan K.K. / SHIONOGI & CO., LTD.
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 5 (410)

Chair: Kazuyuki NAKAGOME (National Center of Neurology and Psychiatry, Japan)

Sponsor: TEIJIN PHARMA LIMITED
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 6 (401+402)

Chair: Toshikazu SAITO (Miki Mental Clinic / Department of Neuropsychiatry, Sapporo Medical University, Japan)

Sponsor: Nippon Shinyaku Co., Ltd.
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 11 (502)

Chair: Tsuyoshi KONDO (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Japan)

Sponsors: KYOWA Pharmaceutical Industry Co., Ltd. / Yoshitomiyakuhin Corporation
*Japanese Session

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 12 (503)

Chair: Soichiro IDE (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Japan)

Sponsor: Philip Morris Japan Ltd.
*Simultaeous interpretation available

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 13 (501)

Chair: Masatoshi TAKEDA (Osaka Kawasaki Rehabilitation University, Japan)

Sponsor: Eisai Co., Ltd.

Sat. Oct 12, 2019 12:30 PM - 1:30 PM Room 15 (Palace Room B)

Chair: Nakao IWATA (Department of Psychiatry, Fujita Health University School of Medicine, Japan)

Sponsor: H. Lundbeck A/S

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 1 (Main Hall)

Chairs: ‌Chan Hyung KIM (Vice-president, AsCNP/ Department of Psychiatry, Yonsei University College of Medicine, Korea), Kazutaka IKEDA (Chair, AsCNP2019/ President, AsCNP/ Addictive Substance Project, Department of Psychiatry and Behavioral Sciences, Japan)

※講演言語：英語

In Asia, a substantial number of patients suffer from neuropsychiatric disorders, and the prevalence of mental health problems, such as schizophrenia, depression, suicide, alcohol and substance abuse, and dementia, is rapidly increasing. To implement measures against these disorders, the Asian College of Neuropsychopharmacology (AsCNP) was founded in 2008. The mission of AsCNP is to encourage research, facilitate the communication of ideas in convergent disciplines of neuropsychopharmacology in Asia, develop new pharmacotherapies for the treatment for psychiatric and neurological disorders, provide education and training opportunities, and empower patients and their families with professional knowledge. AsCNP has society-based and individual-based membership systems. Currently, AsCNP has 9 affiliated societies/sections and more than 50 individual members in 16 countries/regions. Therefore, AsCNP has more than 3200 members (2900 ordinary members and 300 honorary members/student members). The AsCNP congress is regularly held every 2 years. There are two Associate Journals, “Clinical Psychopharmacology and Neuroscience” and “Neuropsychopharmacology Reports.” These current status of AsCNP will be introduced by Prof. Atsumi Nitta, the AsCNP Secretary General. Prof. Chay Hoon Tan, the AsCNP President-elect, will introduce 7th AsCNP Biennial Congress in Singapore in 2021. Prof. Shih-Ku Lin, an AsCNP Vice President, will explain Award Committee as the committee chair. The AsCNP Lundbeck Science Award was launched this year and will continue. Prof. Andi J. Tanra, the AsCNP Past-President Chair of Education Committee, will talk about 1st ASEAN-AsCNP International Neuropsychopharmacology Congress in Yogyakarta, Indonesia in 2019 and 2nd one in the future. Prof. Winston Shen, an AsCNP Advisor, and Prof. Naotaka Shinfuku, the Founding President of Asian Federation of Psychiatric Associations (AFPA), will introduce AFPA and an example of Asian collaborations, the REAP (Research Antipsychotic Prescriptions) study. Prof. Kazutaka Ikeda, the AsCNP President, will talk about related neuropsychopharmacology societies. Collegium Internationale Neuro-Psychopharmacologicum (CINP) is an important partner of AsCNP. The CINP World Congress will be held in Taipei on June 25-28, 2020, and in Tokyo on May 25-28, 2024. American College of Neuropsychopharmacology (ACNP) is also a leader society in neuropsychopharmacology. ACNP provides AsCNP 6-8 slots to participate in their Annual Meeting every year.
AsCNP welcomes neuropsychopharmacologists, psychiatrists, and neurologists, as either individual or society members, in Asia and other regions to join AsCNP and engage in its activities.</rec>

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 2 (411+412)

Chair: ‌Toshihiko MATSUMOTO (Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan)

Sponsor: Meiji Seika Pharma Co., Ltd.
*Japanese Session

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 6 (401+402)

Chair: ‌Shin NAKAGAWA (Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University Graduate School of Medicine, Japan)

Sponsors: SHIONOGI & CO., LTD. / Takeda Pharmaceutical Company Limited
*Japanese Session

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 11 (502)

Chair: Tempei OTSUBO (Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Japan)

Sponsors: MOCHIDA PHARMACEUTICAL CO., LTD. / Mitsubishi Tanabe Pharma Corporation / Yoshitomiyakuhin Corporation
*Japanese Session

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 14 (Palace Room A)

Chair: ‌Norio OZAKI (Department of Psychiatry and Department of Child and Adolescent Psychiatry Nagoya University School of Medicine, Japan)

Sponsor: Astellas Pharma Inc.
*Japanese Session

Sun. Oct 13, 2019 12:30 PM - 1:30 PM Room 15 (Palace Room B)

Chair: Takeshi INOUE (Department of Psychiatry, Tokyo Medical University, Japan)

Sponsors: Japan Medical Office, Takeda Pharmaceutical Company Limited. / Medical Affairs, Lundbeck Japan K.K.
*Japanese Session